hTNFRSF12A

Nomenclature

C57BL/6JSmo-Tnfrsf12atm(hTNFRSF12A)Smoc

Cat. NO.

NM-HU-230046

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
Tnfrsf12a

Model Description

The endogenous mouse Tnfrsf12a gene was replaced by human TNFRSF12A gene.

Validation Data

image.png

Fig.1 Detection of TNFRSF12A expression in adrenal and ovary by RT-PCR. Tissues RNA was extracted from a 11-week-old female WT C57BL/6 mosue and 8-week-old female homozygous hTNFRSF12A knockin mice (n=2), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mRNA primers. Mouse Tnfrsf12a mRNA (135 bp) was detectable only in wild-type C57BL/6 mice. Human TNFRSF12A mRNA (104 bp) was detectable only in homozygous hTNFRSF12A knockin mice but not in wild-type mice. 

Abbr. M, marker; HO, homozygous; WT, wild type.

image.png

Fig.2 Detection of TNFRSF12A expression in hTNFRSF12A mice by WB. The heart, kidney and skeletal muscle tissue lysates were collected from 11-week-old female WT C57BL/6 mice and 8-week-old female homozygous hTNFRSF12A mice, and then analyzed by western blot with anti-TNFRSF12A antibody. Human TNFRSF12A protein was detectable in heart, kidney and skeletal muscle tissues from hTNFRSF12A knockin mice using an antibody cross-reactive between human and mouse TNFRSF12A.

Abbr. HO, homozygous; WT, wild type; PC, positive control, HT-1080 cells; M, marker.

Note. The arrow indicates the target strip.


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more